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Abstract Prospective population based Registers of amyotrophic lateral sclerosis (ALS) have operated in Europe for over two decades, and have provided important insights into our understanding of ALS. Here we review the benefits that population Registers have brought to the understanding of the incidence, prevalence, phenotype and genetics of ALS, and, outline the core operating principles that underlie these Registers and facilitate international collaboration. Going forward we offer lessons learned from our collective experience of operating ALS registers in Europe for over two decades.   
 
Introduction 
Prospectively designed population based registers with complete ascertainment of all affected individuals 
in a defined geographic catchment area are of increasing value in epidemiologic research, as evidenced by 
the success of European population-based registers for Amyotrophic Lateral Sclerosis (ALS)[1,2].  
Although a rare disease with an incidence in Europe of 2-3/100,000 person-years[1,2], ALS provides an 
excellent model to study neurodegenerative diseases. The disease has a rapid progression and is uniformly 
fatal, and there is high clinico-pathological correlation (autopsy diagnosis matches clinical diagnosis), 
rendering in vivo diagnosis accurate in the vast majority of cases. As is the case with other 
neurodegenerations, it is now recognized that ALS is a heterogeneous condition associated with more than 
one pathogenic mechanism and with different clinical manifestations and trajectories. With evolving 
recognition of disease heterogeneity as an important factor in a precision medicine approach towards the 
development of new therapeutics, population based datasets can play a crucial role in defining the full 
range of disease phenotype and demography.  
ALS population based Registers capture all cases regardless of age, health or socioeconomic status, and can 
thus provide a wealth of information about disease incidence, prevalence, spatial distribution, 
heterogeneity in clinical phenotype, outcome and analysis of risk. The Irish and Italian ALS Registers have 
been in continuous operation for over 2 decades, and the Dutch and English for over a decade, during 
which insights into the patho-physiology, epidemiology and genetics of ALS have developed greatly. Each of 
these registers has provided valuable country-specific data regarding epidemiology, disease progression, 
clinical phenotyping and genetics, health service planning, quality of life assessment and mapping of the 
patient journey[2–7].  
The EURALS consortium in Europe, which combines ALS population based Registers from European 
countries, has generated a simplified framework for inclusion in an ALS database including basic 
demographics, El Escorial categorization at diagnosis, site of onset, time from first symptom to onset, 
cognitive status using a standardised screening tool with country specific validation, and genotype if 
known[8]. This has enabled collaboration across European Registers, providing insights that would not be 
 
otherwise possible. For example, combined appraisal of Registers has indicated the presence of population 
based variability, has provided evidence that ALS is a multistep process[5], and has facilitated unbiased 
studies of spatial epidemiology[9–11]. 
The aim of this review is to provide a detailed analysis of what has been learned from existing ALS 
Registers, to identify and to recognize hidden biases and confounders which may affect Registers, and to 
explore future challenges to population based Registers and how these might be met.  
 
 
Incidence and Prevalence of ALS  
Comparative analysis of ALS across European Registers has provided incidence rates of 2.6/100,000 person-
years and prevalence rates of 7-9/100,000 persons, with a mean life expectancy of 30 months from first 
symptoms[2,12,13]. European ALS Registers are well served by the presence of stable populations with 
defined geographic borders ensuring accuracy of incident and prevalent figures [2,14]. All patients are 
captured by population based registers because no patient is too old, too poor or too sick. A stable 
population structure with limited mobility also reduces the risks of loss to follow up. Population based 
Registers differ in this respect from  Registers that are based on service utilization, drug prescription or 
insurance cover, as these are likely to miss patients who do not attend specialists or access services, and 
repositories are accordingly biased. 
In general, multiple data sources provide the best mechanism for accurate data capture[1,14]. Depending 
on the type of health system, European ALS Registers have ascertained patients by a combination of unique 
patient identifiers (UK, Italy), referrals through networks of clinical professionals and death certification 
(Ireland), self-reporting and coding, and face to face or telephone based interviews with self-reported 
questionnaires (Netherlands). To assess the degree of under-ascertainment when two or more 
independent sources are used, a capture-recapture system is often used [13,15], although this is less 
accurate if data sources are linked in any way as has been shown by the Irish Register[16].   
 
 
How hidden bias can affect estimates of incidence  
A number of studies have suggested that the incidence of ALS may be increasing[17–19]. However, careful 
evaluation of European Register data collected over 20 years suggest otherwise[14]. Thus, these apparent 
increases in incidence are most likely to be explained by the increased recognition of phenotypes that 
might in the past have been excluded from collection, including in some patients with “possible ALS” as per 
the EL Escorial diagnostic criteria and those with features of fronto-temporal dementia (FTD), who also 
have a recently recognized associated motor degeneration. Slight changes in accepted criteria for inclusion 
on Registers in turn leads to subtle shifts in ascertainment, as Registers evolve to include patients who 
might otherwise have escaped ascertainment, particularly in later life[20]. The apparent increase in cases is 
contemporaneous with the evolving recognition that ALS patients can experience a range of cognitive 
changes which in some cases may be the presenting symptom[21,22].  Additionally, all Registers, no matter 
how well they are designed, will miss some cases at the beginning. The development of a national Register, 
or indeed the presence of a specialist service within a particular region, can have a secondary effect of 
increasing awareness of the condition, which also improves ascertainment as time goes on. Thirdly, the 
demographics of European countries are such that an increasing proportion of the population has entered 
the age range associated with increased risk of developing ALS. In this instance, although the total number 
of cases of ALS might increase within a population, the standardized rates may not have changed.  
Failure to recognize the inherent biases of subtle changes in disease recognition, coupled with 
improvements in ascertainment strategies and changes in population demography can drive assumptions 
about increasing frequencies of ALS that are not fully supported by appropriately adjusted data.  
 
How biases in datasets can affect survival estimates 
Population based Registers have demonstrated that up to 70% of patients with ALS die within 3 years of 
first symptoms, and that approximately 5-10% can survive for more than 8 years[12,23]. Some clinical trial-
based datasets (e.g. ProACT (https://nctu.partners.org/ProACT) ) have suggested that survival of ALS 
patients has increased over time, and has been attributed in part to increased use of interventions such as 
 
non-invasive ventilation. However, while there is evidence that non-invasive ventilation may affect survival 
in some patients, data from European population based Registers has not identified a significant overall 
effect on survival at population level since the inception of NIV as a standard of care in ALS 
management[12,23]. Moreover, detailed analysis of population based registers suggests that the apparent 
increase in survival described in some clinical trial based datasets is more likely to be a function of 
systematic. European population based Registers have demonstrated that those patients who participate in 
clinical trials, regardless of whether the therapeutic agent has been efficacious, have a different disease 
trajectory compared to the disease trajectory of the overall population based cohort[24]. Table 1 and figure 
1 exemplify this by comparing participants of the Lithium in patients with amyotrophic lateral sclerosis 
(LiCALS) trial to the parent register population, i.e. the South-East England ALS (SEALS) register[25]. This is 
for the reason that trial datasets usually comprise prevalent patients who attend specialist clinics and who 
are sufficiently well to meet trial entry criteria and sufficiently motivated to enroll in clinical trials. It has 
been long recognized that differences in disease trajectories between incident and prevalent cohorts can 
bias survival analyses, and that this bias underpins the differences in clinical characteristics between clinic-
based (primarily prevalent) and population-based (incident and prevalent) cohorts [26]. It is therefore more 
likely that improvements in survival in data repositories such as ProACT are due to subtle differences in the 
composition of disease cohorts rather than a true shift in disease behaviour. However, it is also the case 
that direct comparison of datasets (including Registers), across different epochs as a means of determining 
changes in disease outcome can lead to unintentional bias due to cohort effects. This is one of the reasons 
why the use of historical controls for comparative purposes is therefore not recommended, even when 
using population based data from Registers. This is because most European ALS Registers have shown that 
data captured in the early years of Registers is unlikely to be of the same complexity or quality of 
subsequently captured data. For example, in the Irish ALS Register, a subtle shift in age profile can been 
ascertained within the study cohort [20]. This is most likely to reflect a transition in awareness of disease 
within the elderly population among referring practitioners. Maturing Registers eventually shift detection 
from a mixture of prevalent and incidence cases in the earlier Register years towards ascertainment of 
 
incident cases as the Register became established (Figure 2). Comparative analyses within Registers and 
across different periods must therefore take these potential confounders into account in drawing 
conclusions about disease behaviour.  
 
Expanding the ALS Phenotype  
Italian and Irish ALS Registers provide detailed analyses of disease sub-phenotypes that have helped to 
characterize the clinical and cognitive changes associated with ALS [27–30], demonstrating how Registers 
provide new insights that can help to accurately classify patients into different clinical and prognostic 
subgroups. This can be helpful for clinical trial stratification. For example, Irish and Italian Registers have 
shown that cognitive and behavioural changes are intrinsic features of ALS, affecting up to 50% of 
patients[28], and are associated with significant prognostic implications [29,30]. Interrogation of individual 
datasets can also provide important differentiating features that allow exclusion of possible mimic 
syndromes [31].  
Registers have also been helpful in characterizing the presence of possible endo-phenotypes, among 
probands and their extended family members.  Such population-based observations can in turn lead to 
novel and previously unrecognized pathogenic mechanisms. For example, a recent population based study 
from Ireland has shown higher rates of psychosis and suicide in first and second degree relatives of ALS 
patients compared to controls [32]. This observed family aggregation of neuropsychiatric disorders in ALS 
kindred’s provided the necessary hypothesis to undertake a combined summary statistics GWAS Analysis of 
ALS and schizophrenia which has revealed a hitherto unrecognized 14% polygenic overlap between ALS and 
schizophrenia, suggesting the presence of shared pathogenic mechanisms between these two clinically 
divergent disorders [32]. 
 
Ascertaining Environmental Risk 
While Registers of themselves, cannot define risk, well established population based prospective Registers 
such as the Dutch ALS Register can support detailed population based case control studies aimed to assess 
 
environmental risk, including physical activity, BMI, consumption of alcohol and fat, smoking and other 
exposures [6,33–35]. Because ALS is a rare disease, large case control studies require extensive 
collaboration between different centres and across different geographic regions. Sublte differences in 
ascertainment and disease definition can introduce bias unless the data collection has been standardized 
with respect to ascertainment and characterization. The recent Euro-MOTOR study comprising cases and 
controls from countries with population based Registers demonstrates that combined ascertainment can 
significantly enhance power for risk assessment[36]. The Euro-MOTOR project has now established a 
repository of over 1500 population based incident cases and 3000 matched controls with extensive 
phenotype, environmental, and genomic characterization[36]. The Euro-MOTOR design has since been 
exported to other regions, most recently to 3 Latin American countries (Cuba, Chile and Uruguay) which 
have formed the Latin American Epidemiology Network for ALS (LAENALS).   
Registers can also demonstrate how non-uniformity of access to health systems can bias analyses of risk. 
This is exemplified by conflicting observations relating to the association of disease risk and socioeconomic 
status. For example, an association between ALS with area-based socio-economic status was reported in 
New Jersey [37], where access to health services is not uniform and those in lower socioeconomic groups 
may not be captured. This contrasts with recent analyses from the European Registers, which have not 
demonstrated any association between social deprivation and ALS incidence [9–11].  
Registers can also be used to address claims of disease clustering. Many studies have been published 
suggesting increased rates of ALS in regions thought to be associated with specific risk. This is exemplified 
by the suggestion that environmental pollutants or cyanotoxin exposure are associated with ALS. A 
geographic ascertainment bias (the so called “Texas sharp-shooter phenomenon”) is generated by 
examination of reported clusters in the absence of complete surveillance data [38]. By contrast careful 
population based analysis using well established Registers has to date failed to identify a spatial association 
between specific environmental pollutants and disease risk, as exemplified most recently by the negative 
evidence for clustering in a heavily polluted region of Italy[39]. Indeed, to date other than Guam and the Kii 
peninsula of Japan, no reproducible areas of clustering have been noted. A region of reduced incidence 
 
(“cold spot”) has recently been reported by the Irish Register [40]. The reasons for this are unclear, but may 
be related to subtle historical differences in local population structure.  
 
Making Sense of Genetics   
Defining Familial Disease  
Prior to the recognition of the importance of the C9orf72 repeat expansion as an important causative gene 
in ALS, familial ALS (FALS) has been reported to account for 5% of cases [41]. More detailed analysis of 
family history and genotyping of at least one population based Register (Ireland) now suggests that the true 
proportion of FALS is closer to 16-20% of all ALS cases [32]. Low reported rates of familial disease are most 
likely a function of biased study design that do not collect within a population-based setting. It is also the 
case that incident patients may not be aware of a family history, or may not recognize the link between the 
proband and a family history of progressive neurological decline.  Longer running Registers can provide 
important insights in this regard, as new patients are ascertained within kindred’s that had previously been 
classified as “sporadic”. 
It must also be noted that genetic studies that do not recognize the presence of variations in population 
structure can confound analysis, as the make assumptions of uniform prevalence of gene variants and 
clinical phenotype [42,43]. Variation in the prevalence of at risk genes is known to be the case for at least 
two major ALS genes - the frequency of the C9orf72 repeat expansion is high in populations of European 
extraction and low in the Asian population [44], while variants in SOD1 account for 13% of familial ALS in 
Italy, but are not found in Ireland and are rare in Holland [45]. The presence of population isolates can also 
affect the genetic epidemiology of ALS. For example, higher rates of ALS have been identified in a 
population isolate in The Netherlands, leading to the discovery of ALS associated variants in the NEK1 gene 
[3]. Similarly, higher rates of familial ALS have been noted in Sardinia due to founder effects with respect to 
TDP43 and C9orf72[43]. 
 
It is important to note that Registers can not only help to identify new genes as in the case of NEK1, they 
can also limit the impact of referral bias on genetic studies [46]. Many genetics studies are of necessity 
clinic based, and since it is known that clinic based cohorts are phenotypically distinct from population 
based cohorts (Table 1), it can be assumed that reports of the prevalence of at risk genotypes are also 
biased. It should also be noted that apparently minor differences in selection processes (e.g. clinic rather 
than population based patients, and controls that are not matched) have the potential to influence the 
outcome of genetic association studies.   
Complex Genetics, Ancestral Origin and Disease Risk 
Interrogation of incidence, prevalence and risk genetically admixed populations is of increasing interest. As 
noted, there is now considerable evidence that the incidence of ALS varies significantly across countries 
[47,48] and the phenotype and outcome of the disease vary in relation to population ancestral origin [49]. 
South American populations of mixed ancestral origin may have lower rates of ALS compared with those 
reported in Europe [47,50]. A population based mortality study from Cuba has reported different rates of 
ALS in different ancestral populations, with higher rates in those of European origin and lower rates in the 
admixed population (which corresponds to the “Latino” population in the US) [47]. Population based 
Registers that ascertain within a region of mixed ancestral origin are therefore of particular interest from 
genetic and environmental perspectives. Differences in ancestral risk may be significant sources of bias in 
the generation of Registers in countries such as the US, where differential access to and utilization of health 
services is linked to race, ethnicity, language, rurality, and socioeconomic status [51,52]. The design of 
European population based ALS Registers can counteract such biases by capturing all patients using 
multiple different sources and care pathways [2].  
 
Health Services 
Population based Registers can inform health services. The availability of precise incident, prevalent and 
clinical trajectory data can permit detailed service planning, and can enable projection of future societal 
 
needs. While Registers cannot of themselves provide sufficiently rich datasets to inform the entire patient 
journay, well constructed and compatible Registers within different jurisdictions can also permit 
comparative analyses of different types of services, as has been demonstrated in the island of Ireland [53]. 
Comparison of survival outcome between Registers in the Republic of Ireland and Northern Ireland, which 
have similar population structures but which provide different types of specialist care for ALS patients, have 
shown the multidisciplinary care within a single clinic is superior to devolved care provided within a defined 
“hub and spoke” model of care [53]. Registers also permit high level comparative studies of different 
interventions within individual geographic regions using outcomes such as hospitalizations and survival. In 
Puglia, the model of care is such that there is no survival difference between patients attending local 
neurologists and those receiving care in a specialist multidisciplinary clinic [54]. Similarly, nested work by 
Dutch researchers shows that the additional availability of a regional care worker does not improve quality 
of life among carers [55], although analysis of outcome using population based datasets in the Netherlands 
and Lombardy (Italy) show that multidisciplinary clinics are also better value for money, reduce 
hospitalizations and enhance quality of life of patients [56,57].  
 
Health Services, Clinical Trials and “Real World Data” 
There is an increasing recognition that clinical trials by necessity select patients that are not representative 
of the true population, rendering decisions regarding the generalization of trial findings challenging from a 
health policy perspective [58]. While the best study design for assessment of treatment effectiveness is the 
randomized clinical trial, therapeutic effectiveness can also be assessed in more generalizable context using 
prospective observational studies nested within Registers, as has been demonstrated in the case of 
Riluzole[59]. Prospective cohort studies using population based Registers in which the outcomes are 
collected after exposure, or intervention in patients can provide valuable “real world” information 
regarding the longer term effect of a therapeutic intervention.    
 
Sustainability of Population Based Registers.  
 
Registers are difficult to fund as they are often viewed as infrastructure by research bodies, and as research 
initiatives by health services. Many Registers rely on the energy and interest of a single founder, and are 
challenged at the time of retirement of the key principal investigator, as occurred in the case of the Scottish 
Register on the retirement of the founder clinician, Dr. Robert Swingler. Fortunately, recent recognition of 
the value of the population-based Register for ALS by the Scottish health authorities has enabled the re-
establishment of this valuable resource with the provision of ring fenced funding.    
Long term sustainability of Registers can also be eroded by limitations on the types of data disease 
Registers are permitted to record. While issues of privacy and data protection must be clearly addressed in 
Registers as part of an over-arching governance structure, recent changes in European legislation are of 
potential concern to the operation of true population based Registers. For example, inclusion of data 
relating to living patients without their expressed informed consent is now in breach of European data 
protection laws. As institutional review boards are taking an increasingly stringent position regarding 
patient’s autonomy with the introduction of “consent to contact” requirements, there is now a real risk of 
under-ascertainment of cases.  Without derogation based on the principles of public health benefit, it 
becomes increasingly difficult to create and sustain accurate population based Registers for most 
conditions.  
Legislation providing derogation will require an understanding and recognition by the public of the 
important potential societal benefits of population-based epidemiological research, and in particular the 
potential public health benefit of identifying and communicating data regarding regional variations in 
disease incidence, prevalence and survival. This principle is implicit in the case of notifiable infectious and 
communicable diseases and is of particular import in the case of rare neurodegenerative. This has been 
recognized in some jurisdictions for some types of Registers (e.g. the Irish Cancer Register, and the US ALS 
Registry), and by the International Rare Disease Research Consortium (http://www.irdirc.org/). However, 
there remains a disappointingly limited recognition within the Europe legislature of the significant benefits 
of population based Registers. 
 
 
Conclusions 
Prospective population-based disease registers are invaluable in patient oriented research of rare diseases. 
As exemplified by the success of European ALS Registers, population based databases can identify and 
address biases that are intrinsic to other types of data. While some biases cannot be completely eliminated, 
their recognition can provide the necessary caution in data interpretation. Notwithstanding their 
limitations, Registers can provide unique and often unexpected insights into disease epidemiology and 
pathobiology, and can inform the types of healthcare that are of greatest benefit to patients.  
It is imperative that funding agencies, healthcare providers and institution review bodies recognize the 
value of these types of Registers, particularly in the case of rare disease such as ALS, and that forthcoming 
data protection legislation, while well intentioned and appropriate in many ways, does not compromise our 
ability to fully understand disease heterogeneity, and to continue to improve the lives of patients with ALS 
and related neurodegenerations. 
 
  
 
 Core Recommendations 
• Clearly defined case definitions should be used including inclusion and exclusion criteria.  
• Include a clearly labeled register subsection for cases that should be tracked but do not fulfill the 
formal inclusion criteria.  
• Register variables should be carefully selected and a “core content” paradigm should be agreed in 
advance.  
• International collaborative efforts and/or national merger of data in large countries using multiple 
registers to cover different regions are advisable for rare diseases. 
• Dedicated staff time to ensure effective set-up and maintenance of the register 
• Defined Capture methodology including multiple sources  
• Regular comparison of ascertainment rates and patient demographics  
• Investigation of “ascertainment holes”  
• Employment of careful statistical analyses of data collected in the first 3-5 years to account for 
“start-up bias”  
• Exclude the most recent 1-2 years of data capture, particularly for survival analyses. 
• Security is paramount for system software, yet flexibility to accommodate a shifting knowledge 
base is essential.  
• Including population-based controls in a register enables valuable case-control studies for studying 
environment/lifestyle/genetic risk factors  
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Table 1. Demographic and clinical characteristics of patients enrolled in the LiCALS trial versus the SEALS 
population based register  
Variable SEALS 
(n=296) LiCALS (n=217) Comparison (test) Mean age at onset (years) 63.5 58.0 p-value <0.001 (t test)  Median diagnostic delay (months) 12.5 9.8 p-value <0.001 (Mann-Whitney U)  Sex (M:F %) 52:48 70:30 p-value < 0.001 (Chi squared) Site of onset (%) Bulbar 29.3 21.7 p-value = 0.004 (Chi squared) Spinal 66.9 78.3 Not recorded 3.7 0 El Escorial (%) Definite 27.7 38.2 p-value <0.001 (Chi squared) Probable 48.6 37.3 Clinically probable- laboratory supported 
1.7 18 
Possible 11.8 6.5 Suspected 2.7 0 Not recorded 7.4 0 
Table 1 Legend: Comparison of patients enrolled in the Lithium in patients with amyotrophic lateral 
sclerosis (LiCALS) study[25] compared to the population based South-East England ALS (SEALS) register 
from which participants were recruited. 
 
 
  
 
Table 2. Abridged ENCALS – ALS core clinical dataset 
Personal data Clinical Data Genetics ALSFRS ECAS Cognitive 
and Behavioural 
data 
Date of birth Diagnosis Which ALS genes 
tested ? 
Date of ALS-FRS ECAS additional 
clinical data 
Date of death Date of diagnosis Mutation in ALS 
gene ? 
ALS-FRS 12 
subscores 
ECAS cognitive 
data 
Gender Co-morbidities Free text notes ALS-FRS total 
scores 
ECAS behavioural 
data and carer 
interview 
Patient/control El Escorial category Free text to add 
other genes 
Rater name  
ID numbers Date of disease onset    
Optional 
identifying data 
Site of disease onset    
Free text notes Other first symptoms 
(e.g. weight loss, 
cognitive/behavioural) 
   
 Forced Vital Capacity / 
Sniff nasal inspiratory 
pressure 
   
 Family history    
 Endpoints – date of 
death, date of 
tracheostomy, date of 
   
 
NIV > 23hrs/day, date 
of latest endpoint 
check 
See full ENCALS ALS core clinical data guidelines on the ENCALS website[8]  
 
Figure 1. Kaplan-Meier curve of LiCALS vs SEALS data 
 
Figure 1 Legend: Kaplan-Meier survival curves for patients enrolled in the LiCALS trial (blue) versus the 
population based SEALS register from which participants were recruited. Characteristics of these groups are 
described in Table 1. 
  
 
Figure 2 Proportion of illness prior to diagnosis versus year of death 
 
Figure 2 Legend: The above graph shows time for onset to diagnosis as a proportion of time from onset to 
death by year of death for incident cases on the Irish ALS register from 1995 - 2013. In the early years of the 
register this proportion appears higher before stabilizing to a more consistent ratio after the year 2000. 
This could be representative of improving survival during the early years of the register however this would 
be at odds with our previous survival analysis [13]. Alternatively, this could be explained by the detection of 
‘legacy’ prevalent cases being detected in the early years of a population disease register. Note that this 
graph is generated only from cases diagnosed from 1995 and onwards. If this trend is explained by pre-
existing ‘legacy’ cases in the population, who may have developed the disease some years previously, the 
effect represents a ‘start-up bias’ in the early years of the disease register, as such cases are by definition 
likely to be long survivors. 
  
 
 
 
